Takeda Pharmaceutical Company Limited

Japan is the second-largest individual pharmaceutical market in the world. It accounts for less than 10% of the total global pharma market.

Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.

In January 2016, Horizon acquired Krystexxa from Crealta Holdings. The drug has been approved by the FDA for the treatment of chronic refractory gout.

In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.

The Japanese pharmaceuticals market is not very welcoming to foreign companies. Similarly, the Japanese population is quite loyal to domestic manufacturers.

The gastrointestinal (or GI) drug market in the United States is expected to grow at a CAGR of 5.0% over a five-year period from 2014 to 2019.

Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.

In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.0 million.

In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.0 million.

In its third-quarter earnings conference call, Tesaro (TSRO) narrowed its revenue guidance for fiscal 2018 from the previously projected range of $250 million to $265 million to $258 million to $265 million.

Johnson & Johnson’s (JNJ) Imbruvica generated revenue of $705.0 million in the third quarter.

In the multiple myeloma market, Celgene leads the immunomodulatory agent class of drugs with Revlimid, Pomalyst, and Thalomid.

Takeda Pharmaceutical’s (TKPYY) bid for Shire (SHPG) has piqued a lot of investor interest.

In fiscal 2017, Johnson & Johnson’s (JNJ) blockbuster drug Remicade generated revenues of $6.3 billion, which reflected an ~9.3% decline year-over-year.

In 4Q17, Pfizer’s (PFE) Bosulif generated revenues of $70 million, which reflected ~52% growth on a YoY (year-over-year) basis.

In 1Q17, 2Q17, and 3Q17, Tasigna generated revenues of $411 million, $463 million, and $482 million, respectively.

In December 2017, Novartis (NVS) presented updated results from the Juliet clinical trial, which demonstrated sustained responses of Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL).

In 1Q17, 2Q17, and 3Q17, Roche’s Alecensa reported revenues of 68 million Swiss francs, 80 million Swiss francs, and 96 million Swiss francs, respectively.

Sucampo Pharmaceuticals (SCMP) generated revenues of $61.2 million in 3Q17 compared with $57 million in 3Q16.

In 3Q17, AstraZeneca’s (AZN) Nexium generated revenues of $469.0 million, which reflected an ~9.0% decline on a year-over-year basis.

Sucampo Pharmaceuticals has granted licenses to commercialize a generic or authorized generic of Amitiza in the United States to Par Pharmaceutical and Dr. Reddy’s Laboratories.

EVENITY (romosozumab) is a monoclonal antibody under investigation that acts by inhibiting the activity of sclerostin.

In 1H17, Novartis’s (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis.

In 2Q17, Celgene’s (CELG) Revlimid generated revenues of ~$2.0 billion, which reflected ~20% growth year-over-year and ~8% growth quarter-over-quarter.

In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.

Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.

Gastrointestinal business In 2016, Valeant Pharmaceuticals’ (VRX) gastrointestinal (or GI) franchise saw its revenue fall due to the loss of patent protection for drugs Zegerid and Glumetza in the US market. Furthermore, the authorized generic version of Zegerid was transferred from Valeant’s Branded Rx segment to the Diversified Products segment. However, these negative trends were […]

Despite more competition and pressures, Merck’s Januvia franchise continued to maintain its leadership in the DPP-4 inhibitor class of diabetes drugs.

In Russia, Teva Pharmaceutical has created a strong portfolio of about 300 products and has been extensively developing its research pipeline.

Sanofi (SNY) plans to become a leading company in the CHC business. The asset swap will exclude Boehringer Ingelheim’s CHC business in China.

Financials were the biggest negative contributors to CNJFX’s total returns in the first four months of 2016.

Celgene has been working on its immunomodulatory backbone drugs to develop combination therapies for use in treating all lines of multiple myeloma.

The NHI revises drug prices every two years. During fiscal 2016, a 6.8% reduction in drug prices is expected.

The drug approval process in Japan includes a sequence of non-clinical studies, clinical studies followed by approval review, and post-marketing surveillance.

The Voya Japan TOPIX Index Portfolio – Class A (IJIAX) fell 0.9% in December 2015 from the previous month. In the three- and six-month periods ended December 31, the fund has risen 7.3% and fallen 4.0%, respectively.

In 2014, Mylan earned about 85% of its total revenues from the US generic market, which is the largest generic market in the world.

Performance evaluation The Brown Advisory-WMC Japan Alpha Opportunities Fund (BIAJX) fell by 6.7% in September 2015 from the previous month. In the three- and six-month periods ending September 30, the fund fell by 13.5% and 7.7%, respectively. However, in the YTD (year-to-date) period, the fund was up by 2.9%. For all periods mentioned above except […]

Brown Advisory-WMC Japan Alpha Opportunities Fund doesn’t target a specific segment by market capitalization. Instead, it intends to be benchmark agnostic.